Schizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as second-generation or "atypical" antipsychotics ...

June 4, 2009 — The latest results from the European First Episode Schizophrenia Trial (EUFEST) show that when it comes to improving cognition in patients with schizophrenia, there is little difference ...

The global market for medications addressing psychotic disorders is projected to reach $32.1 billion by 2033, exhibiting a robust compound annual growth rate (CAGR) of 6.5% over the forecast period.

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

SCOTTSDALE, Arizona — Atypical antipsychotics, though not typically considered drugs of abuse, are now being used to enhance the effects of other drugs or as a way to counter the adverse effects of ...